美股三大指数集体收跌；纽约期金首破4000美元/盎司｜南财早新闻

Investment News - Gold prices reached a historic high, with New York futures surpassing $4000 per ounce and London spot prices exceeding $3990 per ounce. Goldman Sachs has raised its gold price forecast for December 2026 to $4900 per ounce from a previous estimate of $4300 [3] - The domestic gold price has also risen in tandem with international prices, leading to a rapid expansion of gold ETF sizes in China, with several products exceeding 10 billion yuan. Analysts attribute this upward trend to expectations of Federal Reserve interest rate cuts and ongoing issues with U.S. dollar credibility [3] - In the first three quarters, Hong Kong's stock exchange ranked first globally in financing, with over 180 billion HKD raised, as overseas funds increasingly flow into emerging markets [3] - Following a global consensus on technology narratives, foreign and QDII funds have been actively investing in Hong Kong's tech sector, which has shown significant growth during the recent holiday period. The expectation is that this sector will continue to thrive with lower financing costs and ongoing technological advancements [3] Company Developments - Tesla has updated the ordering information for its Model Y and Model 3 standard versions, with the Model Y starting at $39,990, approximately 11% cheaper than before, and the Model 3 starting at $36,990, making it Tesla's most affordable model [4] - Mercedes-Benz Group reported a third-quarter sales figure of 525,300 units, a 12% year-on-year decline, with total sales for the first three quarters reaching 1.6 million units, down 9% year-on-year. However, the sales of pure electric vehicles in the third quarter increased by 9% to 51,200 units [4] - Dell Technologies has significantly raised its sales and profit growth forecasts for the next two years, citing strong demand for AI products, with a projected annual sales growth rate of 7% to 9% over the next four years [5] - AstraZeneca announced that its investigational hypertension drug baxdrostat met its primary goal in a late-stage clinical trial for patients with resistant hypertension, significantly lowering blood pressure [5]